Medac’s marketing authorisation extension gives many patients with psoriasis access to guidelines-based MTX therapy for the first time. Click here to view full Press release
Enhancing the potential of methotrexate. Optimise rheumatism treatment in Finland with Metoject® PEN1 and ensure long-term success of therapy Helsinki / Wedel (September 21, 2017). There is room for improvement in drug treatment of rheumatoid arthritis (RA) with the gold standard methotrexate (MTX). Current analyses of the FIN-ERA cohort suggest that Finnish rheumatology exploits the […]
Methotrexate for psoriasis: effective, safe, favourable. Medac with recent data on subcutaneous methotrexate from METOP study at the EADV in Geneva. Geneva / Wedel (September 15, 2017). Methotrexate (MTX) is the most frequently used conventional systemic drug in the treatment of psoriasis. With over 50 years of successful experience in this setting, it is no […]
Enhancing the potential of methotrexate. Optimise rheumatism treatment with Metoject® and ensure long-term success of therapy Stuttgart / Wedel (September 11, 2017). There is room for improvement in drug treatment of rheumatoid arthritis (RA) with the gold standard methotrexate (MTX). Current analyses of the CAPEA cohort suggest that German rheumatology exploits the potential of methotrexate […]
Update on the first-line agent Methotrexate in psoriasis treatment: Intensified dosing and subcutaneous administration recommended British Association of Dermatologists’ guidelines reaffirms the importance of the well- established and inexpensive first-line systemic agent Methotrexate (MTX) for the treatment of patients with all types of psoriasis Recently in The Lancet published METOP trial meets the need of […]
medac passes eco-audit and receives award for environmental management medac Gesellschaft für klinische Spezialpräparate mbH is innovative, successful, sustainable and environment-friendly. The pharmaceutical company has proven that economic prosperity and environmental responsibility are not necessarily a contradiction. To achieve perfect conditions for this objective, medac subjected itself to an auditing procedure according to EMAS and […]
Medac hosts a Satellite symposium at the EULAR conference 2016 in London, with the title Best practice and future perspective of subcutaneous methotrexate. This will take place on Thursday the 9th of June 2016 at 8.15 am – 9.45, Room Capital Suite 2/4. EULAR invitation medac press release EULAR 2016 More information about the congress